Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: cardiovascular disease

FDA Rejects Novartis Bid to Repurpose Inflammation Drug for Heart Attacks

John Miller  |  

ZURICH (Reuters)—The U.S. Food and Drug Administration (FDA) has rejected Novartis’s bid to repurpose a drug now approved for rare inflammatory diseases to be used in a group of heart attack survivors, according to the Swiss drugmaker. The company received an FDA letter turning down its bid to make canakinumab a targeted therapy for those…

Antibodies Against Oxidized Phospholipids Protect Against Osteoporosis

  |  

It has long been known that hyperlipidemia adversely affects bone, but the exact pathologic mechanism(s) underlying hyperlipidemia-induced bone loss has not been fully understood. Until now. Pathogenesis of Osteoporosis New research by Ambrogini and colleagues shows that oxidation-specific epitopes derived from lipid peroxidation contribute to the pathogenesis of osteoporosis.1 Importantly, the research shows that innate…

Study Reveals Lupus Is a Leading Cause of Death in U.S. Women

Kimberly J. Retzlaff  |  

Systemic lupus erythematosus (SLE) is a leading cause of death among young women, according to an August 2018 study in Arthritis & Rheumatology.1 To help determine where SLE ranks among causes of death, Eric Y. Yen, MD, and Ram Raj Singh, MD, conducted a population-based study using nationwide mortality counts for all female residents of…

Placebos: Their Underappreciated Impact in Pharmaceutical Trials

Placebos: Their Underappreciated Impact in Pharmaceutical Trials

Terence W. Starz, MD, Theodore Pincus, MD, On Behalf Of The ARHP Practice Committee  |  

Sir William Osler, the father of modern medicine, said “the desire to take medicine is perhaps the greatest feature that separates man from animal.” Determination of the benefit of a medication can be challenging and includes a number of factors, such as pharmacologic activities on the disease pathophysiology, pharmacokinetic properties and patient characteristics.1,2 An additional,…

Antiphospholipid Syndrome: The Risk of Travel at High Altitudes

Antiphospholipid Syndrome: The Risk of Travel at High Altitudes

Vaneet Kaur Sandhu, MD, & Kathleen Teves, MD  |  

Antiphospholipid syndrome (APS) is an autoimmune clotting disorder that may present catastrophically with multiple thromboses over a short period of time. In this article, we examine the case of a woman with undiagnosed APS whose first symptoms presented during a long-haul flight. A review of the literature on thrombosis at high altitudes and during long…

Statins Linked to Idiopathic Inflammatory Myositis

Will Boggs, MD  |  

NEW YORK (Reuters Health)—Statin use is associated with an increased likelihood of developing idiopathic inflammatory myositis (IIM), researchers from Australia report. “[Although] the incidence of IIM is rare, with the increasing use of statins worldwide and the severity of this condition, this study highlights the need for increased awareness of the condition and the importance…

Medical Tech-Tool Usage Is Surging

  |  

Technology in medicine is no longer new or trendy. It’s pervasive. Rheumatologists may now assume a patient has searched online for information about his or her diagnosis or potential therapies. Both physicians and rheumatology health professionals should acknowledge their patients’ Internet surfing and find out what they’ve read, says Betsy Roth-Wojcicki, RN, MS, CPNP, an…

Researchers Seek to Predict & Prevent Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc, & Kevin D. Deane, MD, PhD  |  

Preventing adverse outcomes in individuals who have rheumatic diseases is a daily goal for rheumatologists. For example, rheumatologists prescribe medications and perform screening to prevent erosions in rheumatoid arthritis (RA), renal failure in systemic lupus erythematosus and flares across all diseases. Many of these actions are classified as secondary or tertiary prevention, because individuals have…